Nalaganje...
Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures
SIMPLE SUMMARY: Currently available biomarkers for response to checkpoint inhibitors are incomplete and predominantly focus on tumor tissue analysis e.g., tumor mutational burden, programmed cell death-ligand 1 (PD-L1) expression. Biomarkers in peripheral blood would allow a more dynamic monitoring...
Shranjeno v:
| izdano v: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8198315/ https://ncbi.nlm.nih.gov/pubmed/34071888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13112630 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|